Celastrol Attenuates RANKL-Induced Osteoclastogenesis <i>in vitro</i> and Reduces Titanium Particle-Induced Osteolysis and Ovariectomy-Induced Bone Loss <i>in vivo</i>.

导出 LinkOut

翻译打印收藏纠错

作者： Qiang,Xu ^[1] ; Guiping,Chen ^[1] ; Huaen,Xu ^[2] ; Guoming,Xia ^[1] ; Meisong,Zhu ^[1] ; Haibo,Zhan ^[1] ; Bin,Zhang ^[1] ; Min,Dai ^[1] ; Hongxian,Fan ^[1] ; Xuqiang,Liu ^[1]

作者单位： Department of Orthopedics, the First Affiliated Hospital of Nanchang University, Artificial Joints Engineering and Technology Research Center of Jiangxi Province, Nanchang, China. ^[1] Department of Ophthalmology, the Affiliated Eye Hospital of Nanchang University, Nanchang, China. ^[2]

关键词 RANKL (receptor activator for nuclear factor-κB ligand)TAK1 binding protein 1 celastrol derivatives osteoclast osteolysis osteoporosis

DOI 10.3389/fphar.2021.682541

PMID 34149427

发布时间 2021-06-22

翻译满意度评价：

准确一般字义偏差语意偏离译文作用小提交

浏览1

Frontiers in pharmacology

2021年12卷

682541页

相似文献

中文期刊
外文期刊
学位论文
会议论文

检索历史清除

Celastrol Attenuates RANKL-Induced Osteoclastogenesis <i>in vitro</i> and Reduces Titanium Particle-Induced Osteolysis and Ovariectomy-Induced Bone Loss <i>in vivo</i>.

Frontiers in pharmacology

相似文献

Frontiers in pharmacology

相关期刊

参考文献：
指定格式：	NoteExpress EndNote RefWorks NoteFirst

检索历史 清除

Celastrol Attenuates RANKL-Induced Osteoclastogenesis <i>in vitro</i> and Reduces Titanium Particle-Induced Osteolysis and Ovariectomy-Induced Bone Loss <i>in vivo</i>.

Frontiers in pharmacology

相似文献

Frontiers in pharmacology

相关期刊

检索历史清除